Agonistas beta2 y antagonistas muscarínicos de acción prolongada / 24 horas en inhalador combinado vs placebo para la enfermedad pulmonar obstructiva crónica (EPOC): obtienen mejoría significativa en función pulmonar y calidad de vida EPOC leve a moderada.
Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease - Maqsood, U - 2019 | Cochrane Library https://t.co/qL3kunLdhf
RT @CochraneAirways: New #CochraneEvidence: Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inha…
RT @ATS_BSHSR: Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for #COPD…
RT @ATS_BSHSR: Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for #COPD…
RT @ATS_BSHSR: Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for #COPD…
RT @ATS_BSHSR: Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for #COPD…
RT @ATS_BSHSR: Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for #COPD…
RT @ATS_BSHSR: Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for #COPD…
Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for #COPD #pulmonary #lung #respiratory https://t.co/9aqfJuFaWR https://t.co/E6iIypEJix
#CochraneEvidence: Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.#FOAMed #RespMed 👉 https://t.co/DCg09kFzIL https://t.co/PnhIBq7xtl
RT @CochraneAirways: Review included 22 RCTs involving 8641 people with COPD (9 crossovers). Participants received either once‐daily LABA/L…
RT @CochraneAirways: New #CochraneEvidence: Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inha…
RT @CochraneAirways: Review included 22 RCTs involving 8641 people with COPD (9 crossovers). Participants received either once‐daily LABA/L…
RT @CochraneAirways: New #CochraneEvidence: Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inha…
RT @CochraneAirways: New #CochraneEvidence: Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inha…
RT @MBResp: LAMA/LABAs good for reducing exacerbation and improving symptom. Worth a read for the details! https://t.co/d9v5dj0HIm
LAMA/LABAs good for reducing exacerbation and improving symptom. Worth a read for the details!
RT @CochraneAirways: Thanks to staff at the following places for doing the Cochrane Review! @SWBHnhs, Firestone Institute for Respiratory H…
Thanks to staff at the following places for doing the Cochrane Review! @SWBHnhs, Firestone Institute for Respiratory Health at @HEI_mcmaster @McMasterForum, @LancashireCare, @HICLancaster @lancasteruni @LancasterMedSch https://t.co/3MdckHp9jI
Review included 22 RCTs involving 8641 people with COPD (9 crossovers). Participants received either once‐daily LABA/LAMA FDC (6252 participants) or placebo (3819 participants) https://t.co/3MdckHp9jI [1/5]
New #CochraneEvidence: Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease https://t.co/1sppKxOV8e
Better together? New review of combination long acting reliever therapies in #COPD from @CochraneAirways https://t.co/NPfDA73WrV